协和医学杂志

2017, v.8(Z2) 244-250

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

抗PUF60抗体在中国特发性炎性肌病患者中的分布及临床意义
The Prevalence and Clinical Usefulness of Anti-PUF60 Autoantibody in Patients with Idiopathic Inflammatory Myopathy

张亚妹;彭清林;卢昕;杨阚波;尹利国;石景丽;陈贺;王国春;
ZHANG Ya-mei;PENG Qing-lin;LU Xin;YANG Han-bo;YIN Li-guo;SHI Jing-li;CHEN He;WANG Guo-chun;Peking University China-Japan Friendship School of Clinical Medicine;Department of Rheumatology,China-Japan Friendship Hospital;

摘要(Abstract):

目的检测抗PUF60抗体在中国特发性炎性肌病(idiopathic inflammatory myopathy,IIM)患者中的阳性率,并探索其临床意义。方法选取1989年10月至2016年8月于中日友好医院住院治疗的388例IIM患者[275例皮肌炎(dermatomyositis,DM)、76例多发性肌炎(polymyositis,PM)及37例肌炎重叠综合征],211例其他自身免疫性疾病患者[28例神经肌肉疾病(noninflammatory neuromuscular disease,NMD)、104例系统性红斑狼疮(systemic lupus erythematosus,SLE)及79例干燥综合征(Sj9gren syndrome,SS)]作为疾病对照组;同时选取门诊体检的167例健康成年人作为健康对照组(healthy controls,HCs)。采用酶联免疫吸附法(enzyme-linked immunosorbent assay,ELISA)检测入组患者及HCs的抗体滴度,并联合免疫印迹实验验证ELISA结果的可靠性。组间比较用独立Mann-Whitney U检验,相关性分析采用Spearman秩检验。结果抗PUF60抗体可见于11.6%(45/388)的IIM患者,17.3%(18/104)的SLE患者,10.1%(8/79)的SS患者,阳性率均高于HCs(IIM比HCs,P<0.001;SLE比HCs,P<0.001;SS比HCs,P=0.009)。且该抗体可见于各IIM亚组,包括11.3%(31/275)的DM患者和21.6%(8/37)的肌炎重叠综合征患者,阳性率均高于HCs(DM比HCs,P<0.001;肌炎重叠综合征比HCs,P<0.001)。此外,抗PUF60抗体在不同自身免疫性疾病中的临床相关性各异。在经典DM中,该抗体常见于肌炎抗体阴性(P=0.018)及并发技工手(P=0.046)的患者;而且该抗体在无肌病性皮肌炎中的阳性率较高,且多伴发皮肤溃疡(P=0.029)。在其他自身免疫性疾病中发现,抗体阳性的SS患者皮疹发生率及类风湿因子、抗SSB抗体、抗RNP抗体阳性比例增加,且抗体阳性的SLE患者外周血CD5+CD19+B细胞数目升高及抗双链DNA、抗Sm、抗SSB抗体阳性比例同样增加(P均<0.05)。结论抗PUF60抗体可见于中国DM、肌炎重叠综合征、SLE和SS患者,且在不同类型自身免疫性疾病中的临床相关性各异,提示抗PUF60抗体或其靶抗原PUF60可能在不同自身免疫性疾病中参与了不同致病过程。
Objective The aim of our study was to detect the positive incidence and analyze the clinical significance of anti-PUF60 antibody in Chinese patients with idiopathic inflammatory myopathy( IIM). MethodsThis study involved,from October 1989 to August 2016,388 IIM patients( including 275 patients with dermatomyositis( DM),76 patients with polymyositis( PM),and 37 patients with myositis overlap syndrome),211 patients with control diseases( including 28 patients with noninflammatory neuromuscular disease( NMD),104 patients with systemic lupus erythematosus( SLE),and 79 patients with Sj9gren's syndrome( SS)) as disease controls,and 167 healthy adults as healthy controls( HCs). Enzyme-linked immunosorbent assay( ELISA) was developed to detect serum anti-PUF60 antibody,and immunoblotting analyses were performed to validate the ELISA results. The results of two groups were compared using unpaired Mann-Whitney U test,and the relevance was analyzed using Spearman correlation analysis. Results Anti-PUF60 antibody was detected in 11. 6%( 45/388) of patients with IIM,17. 3%( 18/104) of patients with SLE,and 10. 1%( 8/79) of patients with SS,and the antibody positive rates were significantly higher than that of HCs( P < 0. 001,P < 0. 001,and P =0. 009,respectively). In IIM subgroups,anti-PUF60 antibody presented in 11. 3%( 31/275) of DM patients and 21. 6%( 8/37) of patients with myositis overlap syndrome,and the antibody positive rates were significantly higher than that of HCs( P = 0. 001 and P < 0. 001,respectively). The clinical associations of anti-PUF60 antibody in different groups of immune disease were varied. Classical DM patients with anti-PUF60 antibody had lower prevalence of currently known myositis antibodies( P = 0. 018) and higher prevalence of mechanic's hands( P = 0. 046). While,the prevalence of anti-PUF60 antibody was particularly higher in the clinically amyopathic dermatomyositisc( CADM),subgroup and associated with the incidence of skin ulcer( P = 0. 029). As for other rheumatic diseases,in SS patients,anti-PUF60 antibody was significantly associated with higher prevalence of cutaneous manifestation,rheumatoid factor,and antibodies against SSB and RNP; in SLE patients,it is related to higher incidence of younger onset, alopecia, hypocomplementemia, elevated CD5+CD19+B-cell subpopulations,and antibodies against ds DNA,Sm and SSB. Conclusions Anti-PUF60 antibody can be detected in Chinese patients with DM,myositis-overlap syndrome,SLE and SS; and it is associated with distinct clinical features in different rheumatic diseases. This finding indicates that anti-PUF60 antibody is associated with different pathogenesis processes in different systemic rheumatic diseases.

关键词(KeyWords): 特发性炎性肌病;抗PUF60抗体;剪接体
idiopathic inflammatory myopathies;anti-PUF60 autoantibody;splicesome

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(91542121,81571603);; 首都卫生发展科研专项项目(2016-2-4063)

作者(Author): 张亚妹;彭清林;卢昕;杨阚波;尹利国;石景丽;陈贺;王国春;
ZHANG Ya-mei;PENG Qing-lin;LU Xin;YANG Han-bo;YIN Li-guo;SHI Jing-li;CHEN He;WANG Guo-chun;Peking University China-Japan Friendship School of Clinical Medicine;Department of Rheumatology,China-Japan Friendship Hospital;

Email:

DOI:

参考文献(References):

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享